BBIO News and Press, BridgeBio Pharma Inc. From 01/30/24

Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics PR Newswire SAN FRANCISCO , Jan. 30, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partner...

2024-01-18 07:50:08 ET More on BridgeBio Pharma BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck BridgeBio Pharma's Robust Pipeline Could Benefit From A Partner BridgeBio Pharma: Taking Some Profits BridgeBio Phase 3 data for ATTR-CM dr...

- The raise includes $500 million in cash from Blue Owl and CPP Investments in exchange for a 5% royalty on future global net sales of acoramidis - The raise also includes a $450 million credit facility from Blue Owl that refinances existing senior secured credit, extending maturity fro...

2024-01-11 17:19:01 ET Summary BridgeBio Pharma, Inc. expects results from the phase 1/2 study, using gene therapy BBP-631 for the treatment of patients with congenital adrenal hyperplasia, in early 2024. The congenital adrenal hyperplasia treatment market is expected to reach $89...

2024-01-11 11:08:51 ET More on BridgeBio Pharma BridgeBio Pharma's Robust Pipeline Could Benefit From A Partner BridgeBio Pharma: Taking Some Profits BridgeBio submits FDA market application for ATTR-CM drug BridgeBio draws Buy rating at Cantor citing 100% up...

- ATTRibute-CM demonstrated a significant treatment effect of acoramidis on the primary endpoint (a hierarchical analysis inclusive of all-cause mortality (ACM) and frequency of cardiovascular-related hospitalization (CVH)), with a Win Ratio of 1.8 (p<0.0001) - Acoramidis demonstrated ...

BridgeBio Pharma, Inc. (NASDAQ: BBIO) is the focus of IBN's latest stock spotlight. The company's shares have moved 4.3% on the day to $25.49. BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 ...

2024-01-08 03:18:45 ET Summary BridgeBio’s FDA filing for acoramidis and advances in KRAS mutation cancer treatment contrast with growing financial losses. Acoramidis competes with Pfizer’s ATTR-CM treatments; BBIO's oncology focus includes promising KRAS inhibitors ...

PALO ALTO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will pre...

The United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for BBO-8520, a first-in-class orally bioavailable and potentially highly potent small molecule direct inhibitor of KRAS G12C that binds to the Switch II pocket in both the ...